APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Type 1 Diabetes Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Type 1 Diabetes Drugs Market Outlook and Growth Opportunities 2026

Report ID 174043920420 December 2025192 pages

Choose your research edition.

Industry ResearchType 1 Diabetes Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Type 1 Diabetes Drugs Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Type 1 Diabetes Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Type 1 Diabetes Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Type 1 Diabetes Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Type 1 Diabetes Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Type 1 Diabetes Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Type 1 Diabetes Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Type 1 Diabetes Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Type 1 Diabetes Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Type 1 Diabetes Drugs market include Sanofi, Novo Nordisk, Eli Lily, AstraZeneca, Diamyd Therapeutics AB, Boehringer Ingelheim, Biodel, BHV Pharma and Astellas Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Type 1 Diabetes Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Type 1 Diabetes Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Type 1 Diabetes Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Type 1 Diabetes Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Type 1 Diabetes Drugs Segment by Company

Sanofi

Novo Nordisk

Eli Lily

AstraZeneca

Diamyd Therapeutics AB

Boehringer Ingelheim

Biodel

BHV Pharma

Astellas Pharma

Adocia

Type 1 Diabetes Drugs Segment by Type

Insulins

Others

Type 1 Diabetes Drugs Segment by Application

Drugstore

Hospital

Others

Type 1 Diabetes Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Type 1 Diabetes Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Type 1 Diabetes Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Type 1 Diabetes Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Type 1 Diabetes Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Type 1 Diabetes Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Type 1 Diabetes Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Type 1 Diabetes Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Type 1 Diabetes Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Type 1 Diabetes Drugs industry.

Chapter 3: Detailed analysis of Type 1 Diabetes Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Type 1 Diabetes Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Type 1 Diabetes Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Type 1 Diabetes Drugs Industry Trends Table 2. Type 1 Diabetes Drugs Industry Drivers Table 3. Type 1 Diabetes Drugs Industry Opportunities and Challenges Table 4. Type 1 Diabetes Drugs Industry Restraints Table 5. Global Type 1 Diabetes Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Type 1 Diabetes Drugs Revenue Share by Company (2021-2026) Table 7. Global Type 1 Diabetes Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Type 1 Diabetes Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Type 1 Diabetes Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Type 1 Diabetes Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Type 1 Diabetes Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Type 1 Diabetes Drugs Company, Product Type & Application Table 13. Global Type 1 Diabetes Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Type 1 Diabetes Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Insulins Table 18. Significant Companies of Others Table 19. Global Type 1 Diabetes Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Type 1 Diabetes Drugs Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Type 1 Diabetes Drugs Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Type 1 Diabetes Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Type 1 Diabetes Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Type 1 Diabetes Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Type 1 Diabetes Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Type 1 Diabetes Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Type 1 Diabetes Drugs Sales Value Share by Type (2021-2026) Table 28. Global Type 1 Diabetes Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Drugstore Table 30. Significant Companies of Hospital Table 31. Significant Companies of Others Table 32. Global Type 1 Diabetes Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Type 1 Diabetes Drugs Sales Volume by Application (2021-2026) & (W Units) Table 34. Global Type 1 Diabetes Drugs Sales Volume by Application (2027-2032) & (W Units) Table 35. Global Type 1 Diabetes Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Type 1 Diabetes Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Type 1 Diabetes Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Type 1 Diabetes Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Type 1 Diabetes Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Type 1 Diabetes Drugs Sales Value Share by Application (2021-2026) Table 41. Global Type 1 Diabetes Drugs Sales Value Share by Application (2027-2032) Table 42. Global Type 1 Diabetes Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Type 1 Diabetes Drugs Sales by Region (2021-2026) & (W Units) Table 44. Global Type 1 Diabetes Drugs Sales Market Share by Region (2021-2026) Table 45. Global Type 1 Diabetes Drugs Sales by Region (2027-2032) & (W Units) Table 46. Global Type 1 Diabetes Drugs Sales Market Share by Region (2027-2032) Table 47. Global Type 1 Diabetes Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Type 1 Diabetes Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Type 1 Diabetes Drugs Sales Value Share by Region (2021-2026) Table 50. Global Type 1 Diabetes Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Type 1 Diabetes Drugs Sales Value Share by Region (2027-2032) Table 52. Global Type 1 Diabetes Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Type 1 Diabetes Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Type 1 Diabetes Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Type 1 Diabetes Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Type 1 Diabetes Drugs Sales by Country (2021-2026) & (W Units) Table 57. Global Type 1 Diabetes Drugs Sales Market Share by Country (2021-2026) Table 58. Global Type 1 Diabetes Drugs Sales by Country (2027-2032) & (W Units) Table 59. Global Type 1 Diabetes Drugs Sales Market Share by Country (2027-2032) Table 60. Global Type 1 Diabetes Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Type 1 Diabetes Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Type 1 Diabetes Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Type 1 Diabetes Drugs Sales Value Market Share by Country (2027-2032) Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Sanofi Type 1 Diabetes Drugs Product Portfolio Table 68. Sanofi Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novo Nordisk Type 1 Diabetes Drugs Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Eli Lily Company Information Table 75. Eli Lily Business Overview Table 76. Eli Lily Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Eli Lily Type 1 Diabetes Drugs Product Portfolio Table 78. Eli Lily Recent Development Table 79. AstraZeneca Company Information Table 80. AstraZeneca Business Overview Table 81. AstraZeneca Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AstraZeneca Type 1 Diabetes Drugs Product Portfolio Table 83. AstraZeneca Recent Development Table 84. Diamyd Therapeutics AB Company Information Table 85. Diamyd Therapeutics AB Business Overview Table 86. Diamyd Therapeutics AB Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Diamyd Therapeutics AB Type 1 Diabetes Drugs Product Portfolio Table 88. Diamyd Therapeutics AB Recent Development Table 89. Boehringer Ingelheim Company Information Table 90. Boehringer Ingelheim Business Overview Table 91. Boehringer Ingelheim Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Boehringer Ingelheim Type 1 Diabetes Drugs Product Portfolio Table 93. Boehringer Ingelheim Recent Development Table 94. Biodel Company Information Table 95. Biodel Business Overview Table 96. Biodel Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Biodel Type 1 Diabetes Drugs Product Portfolio Table 98. Biodel Recent Development Table 99. BHV Pharma Company Information Table 100. BHV Pharma Business Overview Table 101. BHV Pharma Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. BHV Pharma Type 1 Diabetes Drugs Product Portfolio Table 103. BHV Pharma Recent Development Table 104. Astellas Pharma Company Information Table 105. Astellas Pharma Business Overview Table 106. Astellas Pharma Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Astellas Pharma Type 1 Diabetes Drugs Product Portfolio Table 108. Astellas Pharma Recent Development Table 109. Adocia Company Information Table 110. Adocia Business Overview Table 111. Adocia Type 1 Diabetes Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Adocia Type 1 Diabetes Drugs Product Portfolio Table 113. Adocia Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Type 1 Diabetes Drugs Distributors List Table 117. Type 1 Diabetes Drugs Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Type 1 Diabetes Drugs Product Image Figure 2. Global Type 1 Diabetes Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Type 1 Diabetes Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Type 1 Diabetes Drugs Sales (2021-2032) & (W Units) Figure 5. Global Type 1 Diabetes Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Type 1 Diabetes Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Insulins Image Figure 10. Others Image Figure 11. Global Type 1 Diabetes Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Type 1 Diabetes Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Type 1 Diabetes Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Type 1 Diabetes Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Type 1 Diabetes Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Type 1 Diabetes Drugs Sales Value Share by Type (2021-2032) Figure 17. Drugstore Image Figure 18. Hospital Image Figure 19. Others Image Figure 20. Global Type 1 Diabetes Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Type 1 Diabetes Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Type 1 Diabetes Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Type 1 Diabetes Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Type 1 Diabetes Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Type 1 Diabetes Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Type 1 Diabetes Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global Type 1 Diabetes Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Type 1 Diabetes Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Type 1 Diabetes Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Type 1 Diabetes Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Type 1 Diabetes Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Type 1 Diabetes Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Type 1 Diabetes Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Type 1 Diabetes Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Type 1 Diabetes Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Type 1 Diabetes Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Type 1 Diabetes Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Type 1 Diabetes Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Type 1 Diabetes Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Type 1 Diabetes Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Type 1 Diabetes Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Insulins
  • Others
Applications
  • Drugstore
  • Hospital
  • Others
Companies covered
  • Sanofi
  • Novo Nordisk
  • Eli Lily
  • AstraZeneca
  • Diamyd Therapeutics AB
  • Boehringer Ingelheim
  • Biodel
  • BHV Pharma
  • Astellas Pharma
  • Adocia

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Type 1 Diabetes Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Type 1 Diabetes Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Type 1 Diabetes Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Type 1 Diabetes Drugs Market Dynamics
  1. 2.1 Type 1 Diabetes Drugs Industry Trends
  2. 2.2 Type 1 Diabetes Drugs Industry Drivers
  3. 2.3 Type 1 Diabetes Drugs Industry Opportunities and Challenges
  4. 2.4 Type 1 Diabetes Drugs Industry Restraints
3 Type 1 Diabetes Drugs Market by Company
  1. 3.1 Global Type 1 Diabetes Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Type 1 Diabetes Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Type 1 Diabetes Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Type 1 Diabetes Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Type 1 Diabetes Drugs Company Ranking (2024-2026)
  6. 3.6 Global Type 1 Diabetes Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Type 1 Diabetes Drugs Company Product Type and Application
  8. 3.8 Global Type 1 Diabetes Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Type 1 Diabetes Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Type 1 Diabetes Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Type 1 Diabetes Drugs Market by Type
  1. 4.1 Type 1 Diabetes Drugs Type Introduction
  2. 4.1.1 Insulins
  3. 4.1.2 Others
  4. 4.2 Global Type 1 Diabetes Drugs Sales Volume by Type
  5. 4.2.1 Global Type 1 Diabetes Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Type 1 Diabetes Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Type 1 Diabetes Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Type 1 Diabetes Drugs Sales Value by Type
  9. 4.3.1 Global Type 1 Diabetes Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Type 1 Diabetes Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Type 1 Diabetes Drugs Sales Value Share by Type (2021-2032)
5 Type 1 Diabetes Drugs Market by Application
  1. 5.1 Type 1 Diabetes Drugs Application Introduction
  2. 5.1.1 Drugstore
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Type 1 Diabetes Drugs Sales Volume by Application
  6. 5.2.1 Global Type 1 Diabetes Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Type 1 Diabetes Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Type 1 Diabetes Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Type 1 Diabetes Drugs Sales Value by Application
  10. 5.3.1 Global Type 1 Diabetes Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Type 1 Diabetes Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Type 1 Diabetes Drugs Sales Value Share by Application (2021-2032)
6 Type 1 Diabetes Drugs Regional Sales and Value Analysis
  1. 6.1 Global Type 1 Diabetes Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Type 1 Diabetes Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Type 1 Diabetes Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Type 1 Diabetes Drugs Sales by Region (2027-2032)
  5. 6.3 Global Type 1 Diabetes Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Type 1 Diabetes Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Type 1 Diabetes Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Type 1 Diabetes Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Type 1 Diabetes Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Type 1 Diabetes Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Type 1 Diabetes Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Type 1 Diabetes Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Type 1 Diabetes Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Type 1 Diabetes Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Type 1 Diabetes Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Type 1 Diabetes Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Type 1 Diabetes Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Type 1 Diabetes Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Type 1 Diabetes Drugs Sales Value Share by Country, 2025 VS 2032
7 Type 1 Diabetes Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Type 1 Diabetes Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Type 1 Diabetes Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Type 1 Diabetes Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Type 1 Diabetes Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Type 1 Diabetes Drugs Sales by Country (2027-2032)
  6. 7.4 Global Type 1 Diabetes Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Type 1 Diabetes Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Type 1 Diabetes Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Type 1 Diabetes Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Type 1 Diabetes Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Type 1 Diabetes Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Type 1 Diabetes Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Type 1 Diabetes Drugs Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Eli Lily
  14. 8.3.1 Eli Lily Company Information
  15. 8.3.2 Eli Lily Business Overview
  16. 8.3.3 Eli Lily Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lily Type 1 Diabetes Drugs Product Portfolio
  18. 8.3.5 Eli Lily Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Type 1 Diabetes Drugs Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Diamyd Therapeutics AB
  26. 8.5.1 Diamyd Therapeutics AB Company Information
  27. 8.5.2 Diamyd Therapeutics AB Business Overview
  28. 8.5.3 Diamyd Therapeutics AB Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Diamyd Therapeutics AB Type 1 Diabetes Drugs Product Portfolio
  30. 8.5.5 Diamyd Therapeutics AB Recent Developments
  31. 8.6 Boehringer Ingelheim
  32. 8.6.1 Boehringer Ingelheim Company Information
  33. 8.6.2 Boehringer Ingelheim Business Overview
  34. 8.6.3 Boehringer Ingelheim Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim Type 1 Diabetes Drugs Product Portfolio
  36. 8.6.5 Boehringer Ingelheim Recent Developments
  37. 8.7 Biodel
  38. 8.7.1 Biodel Company Information
  39. 8.7.2 Biodel Business Overview
  40. 8.7.3 Biodel Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biodel Type 1 Diabetes Drugs Product Portfolio
  42. 8.7.5 Biodel Recent Developments
  43. 8.8 BHV Pharma
  44. 8.8.1 BHV Pharma Company Information
  45. 8.8.2 BHV Pharma Business Overview
  46. 8.8.3 BHV Pharma Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 BHV Pharma Type 1 Diabetes Drugs Product Portfolio
  48. 8.8.5 BHV Pharma Recent Developments
  49. 8.9 Astellas Pharma
  50. 8.9.1 Astellas Pharma Company Information
  51. 8.9.2 Astellas Pharma Business Overview
  52. 8.9.3 Astellas Pharma Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Astellas Pharma Type 1 Diabetes Drugs Product Portfolio
  54. 8.9.5 Astellas Pharma Recent Developments
  55. 8.10 Adocia
  56. 8.10.1 Adocia Company Information
  57. 8.10.2 Adocia Business Overview
  58. 8.10.3 Adocia Type 1 Diabetes Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Adocia Type 1 Diabetes Drugs Product Portfolio
  60. 8.10.5 Adocia Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Type 1 Diabetes Drugs Value Chain Analysis
  2. 9.1.1 Type 1 Diabetes Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Type 1 Diabetes Drugs Sales Mode & Process
  6. 9.2 Type 1 Diabetes Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Type 1 Diabetes Drugs Distributors
  9. 9.2.3 Type 1 Diabetes Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst